{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:13:11Z","timestamp":1791241991031,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Young children are the population most severely affected by\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    malaria. Seasonal malaria chemoprevention (SMC) with amodiaquine and sulfadoxine-pyrimethamine provides substantial benefit to this vulnerable population, but resistance to the drugs will develop. Here, we evaluate the use of dihydroartemisinin-piperaquine as an alternative regimen in 179 children (aged 2.33\u201358.1 months). Allometrically scaled body weight on pharmacokinetic parameters of piperaquine result in lower drug exposures in small children after a standard mg per kg dosage. A covariate-free sigmoidal\n                    <jats:italic>E<\/jats:italic>\n                    <jats:sub>MAX<\/jats:sub>\n                    -model describes the interval to malaria re-infections satisfactorily. Population-based simulations suggest that small children would benefit from a higher dosage according to the WHO 2015 guideline. Increasing the dihydroartemisinin-piperaquine\u00a0dosage and extending the dose schedule to four monthly doses result in a predicted relative reduction in malaria incidence of up to 58% during the high transmission season. The higher and extended dosing schedule to cover the high transmission period for SMC could improve the preventive efficacy substantially.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-08297-9","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T06:03:17Z","timestamp":1548741797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children"],"prefix":"10.1038","volume":"10","author":[{"given":"Palang","family":"Chotsiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issaka","family":"Zongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-3395","authenticated-orcid":false,"given":"Paul","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-2187","authenticated-orcid":false,"given":"Yves Daniel","family":"Compaore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyir\u00e9kun Fabrice","family":"Som\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Chandramohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warunee","family":"Hanpithakpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7951-0745","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Nosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bosco","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4566-4030","authenticated-orcid":false,"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"8297_CR1","unstructured":"World Health Organization (WHO). World Malaria Report 2018 (2018)."},{"key":"8297_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1586\/eri.10.36","volume":"8","author":"RD Gosling","year":"2010","unstructured":"Gosling, R. D., Cairns, M. E., Chico, R. M. & Chandramohan, D. Intermittent preventive treatment against malaria: an update. Expert. Rev. Anti. Infect. Ther. 8, 589\u2013606 (2010).","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"8297_CR3","doi-asserted-by":"publisher","first-page":"e11225","DOI":"10.1371\/journal.pone.0011225","volume":"5","author":"K Bojang","year":"2010","unstructured":"Bojang, K. et al. A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS. One. 5, e11225 (2010).","journal-title":"PLoS. One."},{"key":"8297_CR4","doi-asserted-by":"publisher","first-page":"e7164","DOI":"10.1371\/journal.pone.0007164","volume":"4","author":"B Cisse","year":"2009","unstructured":"Cisse, B. et al. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS. One. 4, e7164 (2009).","journal-title":"PLoS. One."},{"key":"8297_CR5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1128\/AAC.01413-09","volume":"54","author":"AF Some","year":"2010","unstructured":"Some, A. F. et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob. Agents Chemother. 54, 1949\u20131954 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR6","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1128\/AAC.04923-14","volume":"59","author":"I Zongo","year":"2015","unstructured":"Zongo, I. et al. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob. Agents Chemother. 59, 4387\u20134396 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR7","doi-asserted-by":"publisher","first-page":"e6358","DOI":"10.1371\/journal.pone.0006358","volume":"4","author":"J Zwang","year":"2009","unstructured":"Zwang, J. et al. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS. One. 4, e6358 (2009).","journal-title":"PLoS. One."},{"key":"8297_CR8","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1128\/AAC.05756-11","volume":"56","author":"J Tarning","year":"2012","unstructured":"Tarning, J. et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob. Agents Chemother. 56, 1997\u20132007 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR9","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1128\/AAC.03314-14","volume":"58","author":"BR Moore","year":"2014","unstructured":"Moore, B. R. et al. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob. Agents Chemother. 58, 5784\u20135794 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/clpt.2011.254","volume":"91","author":"J Tarning","year":"2012","unstructured":"Tarning, J. et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin. Pharmacol. Ther. 91, 497\u2013505 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"8297_CR11","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3109\/00498254.2012.693972","volume":"42","author":"TM Lee","year":"2012","unstructured":"Lee, T. M. et al. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica; fate Foreign Compd. Biol. Syst. 42, 1088\u20131095 (2012).","journal-title":"Xenobiotica; fate Foreign Compd. Biol. Syst."},{"key":"8297_CR12","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1124\/dmd.106.011494","volume":"34","author":"J Tarning","year":"2006","unstructured":"Tarning, J. et al. Characterization of human urinary metabolites of the antimalarial piperaquine. Drug Metab. Dispos.: Biol. fate Chem. 34, 2011\u20132019 (2006).","journal-title":"Drug Metab. Dispos.: Biol. fate Chem."},{"key":"8297_CR13","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1128\/AAC.49.6.2407-2411.2005","volume":"49","author":"IK Sim","year":"2005","unstructured":"Sim, I. K., Davis, T. M. & Ilett, K. F. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob. Agents Chemother. 49, 2407\u20132411 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40261-015-0312-8","volume":"35","author":"SE Reuter","year":"2015","unstructured":"Reuter, S. E. et al. Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Clin. Drug. Investig. 35, 559\u2013567 (2015).","journal-title":"Clin. Drug. Investig."},{"key":"8297_CR15","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1128\/AAC.00279-11","volume":"55","author":"A Annerberg","year":"2011","unstructured":"Annerberg, A. et al. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob. Agents Chemother. 55, 3971\u20133976 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR16","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1128\/AAC.02318-13","volume":"58","author":"J Tarning","year":"2014","unstructured":"Tarning, J. et al. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob. Agents Chemother. 58, 2052\u20132058 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0908-8","volume":"14","author":"K Sundell","year":"2015","unstructured":"Sundell, K. et al. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Malar. J. 14, 368 (2015).","journal-title":"Malar. J."},{"key":"8297_CR18","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1128\/AAC.05877-11","volume":"56","author":"KM Lwin","year":"2012","unstructured":"Lwin, K. M. et al. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob. Agents Chemother. 56, 1571\u20131577 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR19","doi-asserted-by":"publisher","first-page":"260ra147","DOI":"10.1126\/scitranslmed.3005311","volume":"6","author":"M Bergstrand","year":"2014","unstructured":"Bergstrand, M., Nosten, F., Lwin, K. M., Karlsson, M. O., White, N. J. & Tarning, J. Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention. Sci. Transl. Med. 6, 260ra147 (2014).","journal-title":"Sci. Transl. Med."},{"key":"8297_CR20","doi-asserted-by":"publisher","first-page":"e1001689","DOI":"10.1371\/journal.pmed.1001689","volume":"11","author":"V Bigira","year":"2014","unstructured":"Bigira, V. et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS. Med. 11, e1001689 (2014).","journal-title":"PLoS. Med."},{"key":"8297_CR21","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/cid\/ciu150","volume":"58","author":"JI Nankabirwa","year":"2014","unstructured":"Nankabirwa, J. I. et al. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin. Infect. Dis. 58, 1404\u20131412 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"8297_CR22","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1038\/psp.2014.29","volume":"3","author":"J Tarning","year":"2014","unstructured":"Tarning, J. et al. Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand. CPT Pharmacomet. Syst. Pharmacol. 3, e132 (2014).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"8297_CR23","doi-asserted-by":"publisher","first-page":"e1001564","DOI":"10.1371\/annotation\/3db421e4-3e27-4442-8092-2ad1b778f371","volume":"10","author":"The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group..","year":"2013","unstructured":"The World Wide Antimalarial Resistance Network (WWARN) DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS. Med. 10, e1001564 (2013).","journal-title":"PLoS. Med."},{"key":"8297_CR24","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1128\/AAC.00486-07","volume":"51","author":"RN Price","year":"2007","unstructured":"Price, R. N. et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob. Agents Chemother. 51, 4090\u20134097 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR25","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1086\/344647","volume":"35","author":"MB Denis","year":"2002","unstructured":"Denis, M. B. et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin. Infect. Dis. 35, 1469\u20131476 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"8297_CR26","unstructured":"World Health Organization. Guidelines for the treatment of malaria, Third edn. (WHO, Geneva, 2015)."},{"key":"8297_CR27","doi-asserted-by":"publisher","first-page":"873","DOI":"10.4269\/ajtmh.2010.10-0158","volume":"83","author":"D Creek","year":"2010","unstructured":"Creek, D. et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria. Am. J. Trop. Med. Hyg. 83, 873\u2013875 (2010).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"8297_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1128\/AAC.00555-07","volume":"52","author":"HA Karunajeewa","year":"2008","unstructured":"Karunajeewa, H. A. et al. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob. Agents Chemother. 52, 237\u2013243 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1046\/j.1365-2125.2003.02004.x","volume":"57","author":"TY Hung","year":"2004","unstructured":"Hung, T. Y. et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57, 253\u2013262 (2004).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"8297_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-398","volume":"11","author":"RM Hoglund","year":"2012","unstructured":"Hoglund, R. M. et al. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar. J. 11, 398 (2012).","journal-title":"Malar. J."},{"key":"8297_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00228-010-0804-7","volume":"66","author":"EA Ashley","year":"2010","unstructured":"Ashley, E. A. et al. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 66, 705\u2013712 (2010).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"8297_CR32","doi-asserted-by":"publisher","first-page":"e50036","DOI":"10.1371\/journal.pone.0050036","volume":"8","author":"A Ouedraogo","year":"2013","unstructured":"Ouedraogo, A. et al. Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso. PLoS ONE 8, e50036 (2013).","journal-title":"PLoS ONE"},{"key":"8297_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1017\/S0031182001001202","volume":"124","author":"JA Simpson","year":"2002","unstructured":"Simpson, J. A., Aarons, L., Collins, W. E., Jeffery, G. M. & White, N. J. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology 124, 247\u2013263 (2002).","journal-title":"Parasitology"},{"key":"8297_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1731-1","volume":"16","author":"NJ White","year":"2017","unstructured":"White, N. J. Malaria parasite clearance. Malar. J. 16, 88 (2017).","journal-title":"Malar. J."},{"key":"8297_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S1471-4922(02)02373-5","volume":"18","author":"NJ White","year":"2002","unstructured":"White, N. J. The assessment of antimalarial drug efficacy. Trends Parasitol. 18, 458\u2013464 (2002).","journal-title":"Trends Parasitol."},{"key":"8297_CR36","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1128\/AAC.41.7.1413","volume":"41","author":"NJ White","year":"1997","unstructured":"White, N. J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41, 1413\u20131422 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR37","doi-asserted-by":"crossref","unstructured":"Permala J., Tarning J., Nosten F., White N. J., Karlsson M. O., Bergstrand M. Prediction of improved antimalarial chemoprevention with weekly dosing of dihydroartemisinin-piperaquine. Antimicrob. Agents Chemother. 61, e02491-16\u00a0(2017).","DOI":"10.1128\/AAC.02491-16"},{"key":"8297_CR38","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1128\/AAC.47.4.1391-1394.2003","volume":"47","author":"LK Basco","year":"2003","unstructured":"Basco, L. K. & Ringwald, P. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob. Agents Chemother. 47, 1391\u20131394 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR39","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1128\/AAC.05141-14","volume":"59","author":"P Tumwebaze","year":"2015","unstructured":"Tumwebaze, P. et al. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children. Antimicrob. Agents Chemother. 59, 3018\u20133030 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR40","doi-asserted-by":"crossref","unstructured":"Rasmussen S. A., et al. Changing antimalarial drug sensitivities in Uganda. Antimicrob. Agents Chemother. 61, e01516\u201317 (2017).","DOI":"10.1128\/AAC.01516-17"},{"key":"8297_CR41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/0091270007310384","volume":"48","author":"T Ahmed","year":"2008","unstructured":"Ahmed, T. et al. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J. Clin. Pharmacol. 48, 166\u2013175 (2008).","journal-title":"J. Clin. Pharmacol."},{"key":"8297_CR42","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1128\/IAI.01147-07","volume":"76","author":"I Nebie","year":"2008","unstructured":"Nebie, I. et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect. Immun. 76, 759\u2013766 (2008).","journal-title":"Infect. Immun."},{"key":"8297_CR43","unstructured":"World Health Organization. Guidelines for the treatment of malaria. (WHO, Geneva, 2010)."},{"key":"8297_CR44","first-page":"227","volume":"862","author":"N Lindegardh","year":"2008","unstructured":"Lindegardh, N., Annerberg, A., White, N. J. & Day, N. P. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. 862, 227\u2013236 (2008).","journal-title":"J. Chromatogr."},{"key":"8297_CR45","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1128\/AAC.02362-14","volume":"58","author":"C Lourens","year":"2014","unstructured":"Lourens, C. et al. Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN). Antimicrob. Agents Chemother. 58, 3889\u20133894 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8297_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer, R. J., van Benten, M., Beijnen, J. H., Schellens, J. H. & Huitema, A. D. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput. Methods Prog. Biomed. 101, 72\u201379 (2011).","journal-title":"Comput. Methods Prog. Biomed."},{"key":"8297_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom, L., Ribbing, J. & Jonsson, E. N. Perl-speaks-NONMEM (PsN)\u2013a Perl module for NONMEM related programming. Comput. Methods Prog. Biomed. 75, 85\u201394 (2004).","journal-title":"Comput. Methods Prog. Biomed."},{"key":"8297_CR48","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1023\/A:1022972420004","volume":"29","author":"PO Gisleskog","year":"2002","unstructured":"Gisleskog, P. O., Karlsson, M. O. & Beal, S. L. Use of prior information to stabilize a population data analysis. J. Pharmacokinet. Pharmacodyn. 29, 473\u2013505 (2002).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"8297_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson, B. J. & Holford, N. H. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug. Metab. Pharmacokinet. 24, 25\u201336 (2009).","journal-title":"Drug. Metab. Pharmacokinet."},{"key":"8297_CR50","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1086\/427243","volume":"191","author":"P Bejon","year":"2005","unstructured":"Bejon, P. et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191, 619\u2013626 (2005).","journal-title":"J. Infect. Dis."},{"key":"8297_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand, M., Hooker, A. C., Wallin, J. E. & Karlsson, M. O. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13, 143\u2013151 (2011).","journal-title":"AAPS J."},{"key":"8297_CR52","unstructured":"World Health Organization. Sigma-tau: Application for Inclusion of Dihydroartemisinin Plus Piperaquine (DHA\/PPQ) Fixed Dose Combination Tablets in the 17th edition of WHO Model Lists of Essential Medicines. (WHO, Geneva, 2010)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08297-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08297-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08297-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T14:38:07Z","timestamp":1671201487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08297-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["8297"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-08297-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"8 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"480"}}